These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18190609)

  • 21. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.
    Bamias G; Kaltsa G; Siakavellas SI; Papaxoinis K; Zampeli E; Michopoulos S; Zouboulis-Vafiadis I; Ladas SD
    Clin Immunol; 2010 Nov; 137(2):242-9. PubMed ID: 20675196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease.
    Rus V; Zernetkina V; Puliaev R; Cudrici C; Mathai S; Via CS
    Clin Immunol; 2005 Oct; 117(1):48-56. PubMed ID: 15961346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble interleukin 2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus.
    Raziuddin S; al-Janadi MA; al-Wabel AA
    J Rheumatol; 1991 Jun; 18(6):831-6. PubMed ID: 1680190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two systemic lupus erythematosus (SLE) global disease activity indexes--the SLE Disease Activity Index and the Systemic Lupus Activity Measure--demonstrate different correlations with activation of peripheral blood CD4+ T cells.
    Daca A; Czuszyńska Z; Smoleńska Z; Zdrojewski Z; Witkowski JM; Bryl E
    Hum Immunol; 2011 Dec; 72(12):1160-7. PubMed ID: 21906646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defects in Notch1 upregulation upon activation of T Cells from patients with systemic lupus erythematosus are related to lupus disease activity.
    Sodsai P; Hirankarn N; Avihingsanon Y; Palaga T
    Lupus; 2008 Jul; 17(7):645-53. PubMed ID: 18625637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decoy receptor 3 protects non-obese diabetic mice from autoimmune diabetes by regulating dendritic cell maturation and function.
    Wang YL; Chou FC; Sung HH; Fan PL; Hsueh CW; Lin WC; Chen SJ; Lin WW; Sytwu HK
    Mol Immunol; 2010 Oct; 47(16):2552-62. PubMed ID: 20801512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies on Fas ligand expression in patients with systemic lupus erythematosus].
    Feng Y
    Hokkaido Igaku Zasshi; 1997 Jul; 72(4):443-55. PubMed ID: 9266252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.
    Blanco P; Pitard V; Viallard JF; Taupin JL; Pellegrin JL; Moreau JF
    Arthritis Rheum; 2005 Jan; 52(1):201-11. PubMed ID: 15641052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of T-cell responses to alloantigens by TR6/DcR3.
    Zhang J; Salcedo TW; Wan X; Ullrich S; Hu B; Gregorio T; Feng P; Qi S; Chen H; Cho YH; Li Y; Moore PA; Wu J
    J Clin Invest; 2001 Jun; 107(11):1459-68. PubMed ID: 11390428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
    Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
    Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
    Wong CK; Lit LC; Tam LS; Li EK; Lam CW
    Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
    Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
    Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population.
    Wu O; Chen GP; Chen H; Li XP; Xu JH; Zhao SS; Sheng J; Feng JB; Cai J; Fang XH; Zhang WH; Li LH; Zhang N; Li J; Li JJ; Pan FM; Wang CZ; Ye DQ
    Immunobiology; 2009; 214(5):392-402. PubMed ID: 19362685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice.
    Ka SM; Sytwu HK; Chang DM; Hsieh SL; Tsai PY; Chen A
    J Am Soc Nephrol; 2007 Sep; 18(9):2473-85. PubMed ID: 17687076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
    Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
    Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
    Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decoy Receptor 3 Suppresses T-Cell Priming and Promotes Apoptosis of Effector T-Cells in Acute Cell-Mediated Rejection: The Role of Reverse Signaling.
    Weng SC; Wen MC; Hsieh SL; Chen NJ; Tarng DC
    Front Immunol; 2022; 13():879648. PubMed ID: 35720343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares.
    Amoura Z; Combadiere C; Faure S; Parizot C; Miyara M; Raphaël D; Ghillani P; Debre P; Piette JC; Gorochov G
    Arthritis Rheum; 2003 Dec; 48(12):3487-96. PubMed ID: 14673999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
    Ezzat M; El-Gammasy T; Shaheen K; Shokr E
    Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.